Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myelomaA. Keith Stewart, Jesús G. Berdeja, Seema Singhal et al.|Blood Cancer Journal|2019Cited by 62